Adverse events · Adults undergoing pelvic radiotherapy
1 finding from 1 review
no estimate extracted
905 participants
Very low
Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
Adverse events ‐ Metformin plus liraglutide vs metformin Nausea Diarrhoea Headache · obese women with subfertility
It is very uncertain whether pharmacological intervention changes adverse events ‐ Metformin plus liraglutide vs metformin Nausea… compared with pharmacological intervention (very low certainty).
1 finding from 1 review
Adverse events (proportion) ‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (GI) · obese women with subfertility
It is very uncertain whether pharmacological intervention changes adverse events (GI) compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: death (secondary outcome) compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
acceptability ‐ drop‐outs due to adverse events: post‐intervention · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to adverse events: post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
1 finding from 1 review
Adverse events: all ‐ central nervous system events (e.g. headache, seizures) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ central nervous system events (e.g. headache,… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: all ‐ other events ‐ not listed above (e.g. dysuria, neck pain, eye discomfort) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ other events ‐ not listed above (e.g.… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ gastrointestinal effects (e.g. constipation,… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ central nervous system events (e.g. confusion,… compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (control ‐ placebo) · young people
3 findings from 1 review
no estimate extracted
1 study · 207 participants
Very low
no estimate extracted
1 study · 211 participants
Very low
no estimate extracted
2 studies · 385 participants
Very low
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Adverse events: death ‐ at end of treatment (Analysis 1.14) · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes adverse events: death ‐ at end of treatment Analysis 1.12 compared with placebo (very low certainty).
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Adverse events · spatial neglect or inattention following stroke and other adult‐acquired non‐progressive brain injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · spatial neglect or inattention following stroke and other adult‐acquired non‐progressive brain injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found